Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01090739 · ClinicalTrials.gov registry record · NA

Clinical Study to Investigate the Effectiveness of the TOPAS System to Treat Fecal Incontinence

A NA study, sponsored by ASTORA Women's Health.

Completed
Registry status
NA
Development phase
207
Enrollment target

NCT01090739: Completed NA study, sponsored by ASTORA Women's Health.

NCT01090739 is a NA study that has completed, run by ASTORA Women's Health. The registered enrollment target is 207 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01090739, a NA study, has completed, sponsored by ASTORA Women's Health.

COMPLETED
Registry status
NA
Development phase
207 participants
Enrollment target

Study Summary

The purpose of this study is to demonstrate that the TOPAS System effectively treats fecal incontinence in women as measured by a 50% reduction in the number of FI episodes in a 14 day bowel diary at 12 months.

Primary Outcome

The primary endpoint for efficacy is the 14 day bowel diary documenting liquid or solid fecal incontinence episodes. A 50% reduction in the number of FI episodes is considered a treatment responder.

Interventions

  • DEVICE TOPAS Treatment for Fecal Incontinence

Trial Details

FieldValue
Enrollment Target 207 participants
Start Date 2010-04
Est. Completion 2016-04
Phase NA
ASTORA Women's Health

7 total trials

What the finished NCT01090739 record still lists

NCT01090739 is an interventional study that assigns participants to a tested intervention. The registered 207 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).

The record links to 0 conditions, and to 1 intervention - of which TOPAS Treatment for Fecal Incontinence is the first listed.

NCT01090739 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01090739 about?

NCT01090739 is a clinical study titled "Clinical Study to Investigate the Effectiveness of the TOPAS System to Treat Fecal Incontinence". The purpose of this study is to demonstrate that the TOPAS System effectively treats fecal incontinence in women as measured by a 50% reduction in the number of FI episodes in a 14 day bowel diary at 12 months.

What is the current status of trial NCT01090739?

This trial is currently completed. It is a NA study. The enrollment target is 207 participants. The study started on 2010-04. Estimated completion is 2016-04.

What interventions are being tested in trial NCT01090739?

The interventions under investigation include: TOPAS Treatment for Fecal Incontinence (DEVICE).

Who is sponsoring clinical trial NCT01090739?

This trial is sponsored by ASTORA Women's Health, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01090739's enrollment target sits among peer trials

207 499th of 2000 higher than 1,502 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04353778 · 207 participants · Phase 1

    Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV

  • NCT05875805 · 207 participants · NA

    A Telehealth Advance Care Planning Intervention

  • NCT06254950 · 207 participants · Phase 2

    A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

  • NCT06904274 · 207 participants · Phase 3

    Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01090739, the US trial registry maintained by the National Library of Medicine. NCT01090739 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.